Composition for normalisation of microflora and cleaning organism from toxins and organism recovery method

FIELD: food industry.

SUBSTANCE: invention relates to production of functional food products and biologically active food additives. The composition for normalisation of microflora and cleaning organism from toxins contains at least one insoluble enterosorbent, at least one prebiotic, at least one edible fat of dodecanic type with a melting temperature of no higher than 39°C. The enterosorbent and prebiotic are introduced as a powder with particles sized no more than 65 mcm. The composition includes components at the following ratio, wt %: enterosorbent - 3-47%; prebiotic - 3-47%; edible fat of dodecanic type - 15-55%; moisture content - no more than 2.5 %. The method for the organism detoxication and recovery is as follows: it ensures simultaneous intake of the enterosorbent as well as the prebiotic and the fat of dodecanic type at least two times a day during 2-3 weeks by way of oral ingestion of the said composition. The composition is ingested in an amount of 50-250 g a day. Preferably, the product is ingested no less than 1 hour prior to meals or 1 hour after meals.

EFFECT: invention ensures complete the organism recovery due to immediate removal of toxins from all sections of the digestive system including the whole of the digestive system with simultaneous normalisation its microflora make-up including prevention of enteral dysbiosis in the process of antibiotic therapy as well as extension of the range of compositions fit for cleaning the organism from toxins and normalisation of microflora.

18 cl, 6 dwg, 12 tbl, 10 ex

 

The text descriptions are given in facsimile form.

1. Composition for the normalization of microflora and cleanse the body from toxins, containing at least one insoluble enterosorbent, at least one prebiotic and at least one edible fat lauric type with a melting point of no higher than 39°C, and the enterosorbent and prebiotic made in the form of a powder with a particle size of not more than 65 μm, with the following content, wt.%:

enterosorbent3-47%
prebiotic3-47%
dietary fat is lauric type15-55%,

when the moisture content in the composition is not more than 2.5%.

2. The composition according to claim 1, characterized in that the insoluble enterosorbent is an insoluble dietary fiber from the group of lignin, fiber, bran, cellulose and its esters, microcrystalline cellulose, vysokotarifitsirovannyh insoluble pectin or mineral substance from the group of zeolite, smectite, and silica (credit the deposits dioxide), activated carbon.

3. The composition according to claim 1, characterized in that it contains a prebiotic in the form of oligosaccharide from the group: lactulose, lactitol, fructo-oligosaccharides, galactooligosaccharides, xylooligosaccharides, maltooligosaccharide, inulin, arabinogalactan, isomalt.

4. The composition according to claim 1, characterized in that it contains dietary fat lauric type from the group of substitutes for cocoa butter-lauric type, coconut oil, palm kernel oil.

5. Composition according to any one of claims 1 to 4, characterized in that it contains enterosorbent humidity less than 5%.

6. Composition according to any one of claims 1 to 4, characterized in that it further comprises at least one flavoring, mainly food flavor, or concealer taste.

7. Composition according to any one of claims 1 to 4, characterized in that it further comprises at least one natural or identical to natural food dye in an amount of not more than 3 wt.%.

8. Composition according to any one of claims 1 to 4, characterized in that it is made of a homogeneous consistence in solid form.

9. The composition according to claim 8, characterized in that it contains as an emulsifier lecithin in an amount not more than 1 wt.%.

10. The composition according to claim 9, characterized in that it is made by casting the melt into molds.

11. Composition according to any one of PP and 10, characterized in that it is Olney in the form of lozenges (tile, bar) any technically implemented with the casting shape, such as oval, round, rectangular, square shape or in the form of nuts, coffee beans, figurines of animals or fish or other

12. Composition according to any one of claims 1 to 4, characterized in that it is made of a homogeneous consistence in pasty form.

13. The composition according to item 12, characterized in that it contains as a diluent excipient is a liquid paraffin in an amount up to 20 wt.%.

14. Composition according to any one of claims 1 to 4, characterized in that it contains any acceptable pharmaceutical or food excipient, providing adequate structural-mechanical, physico-chemical properties of the composition, in accordance with its consumer form and purpose, as well as substances such as preservatives, antioxidants, contributing to the preservation of properties of the composition during storage.

15. Way of detoxifying and healing the body, which provide simultaneous receipt of enterosorbent in the form of insoluble dietary fiber or mineral sorbent, as well as prebiotic and fat lauric type for which at least two times a day, in 2-3 weeks take oral composition according to any one of § § 11-14 in the amount of from 50 to 250 g per day.

16. The method according to 14, characterized in that the enterosorbent taking the Ute in an amount not more than 10 g, prebiotic - not more than 5 g lactulose or not more than 20 g of oligosaccharides from the group:
fructo-oligosaccharides, galactooligosaccharides, xylooligosaccharides or arabinogalactan per day, and dietary fat lauric type - in the form of medium chain fats - saturated fatty acids not more than 12 grams per day.

17. The method according to any of PP and 16, characterized in that for children given amounts taken in proportion to the decrease in the child's body weight compared with the weight of the average person.

18. The method according to any of PP and 16, characterized in that the product take at least 1 hour before a meal or 1 hour after a meal.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to field of immunology and biotechnology. Claimed are: versions of antibody and antigen-binding fragments of antibody to receptor Il-6 of humans. Considered are: isolated molecule of nucleic acid and vector which contains it. Described are: system "host-vector" and method of obtaining antibody or its antigen-binding fragment, as well as application of antibody or its antigen-binding fragment for obtaining medication.

EFFECT: invention application provides novel antibodies to receptor IL-6 of humans, which can be applied in therapy of IL-6- mediated diseases.

11 cl, 5 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology and particularly to obtaining guanylate cyclase receptor-activating peptides and can be used in medicine. A recombinant technique or chemical synthesis is used to obtain a polypeptide consisting of an amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys.

EFFECT: invention enables to obtain a guanylate cyclase-activating polypeptide, and can be used for efficient treatment of gastrointestinal disorders or visceral pain in a patient.

17 cl, 55 dwg, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to novel derivatives of pyridine, of general formula I, where R represents hydroxyalkyl group with normal non-branched chain, which has 5-10 carbon atoms or its pharmaceutically acceptable salt. Also, invention relates to method of obtaining compound of formula I, pharmaceutical composition based on formula I compound, as well as preventive and therapeutic anti-Helicobacter pylori medicine based on formula I compound.

EFFECT: obtained is novel pyridine derivative, which has anti-Helicobacter pylori activity.

24 cl, 4 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to novel derivatives of pyridine, of general formula I, where R represents hydroxyalkyl group with normal non-branched chain, which has 5-10 carbon atoms or its pharmaceutically acceptable salt. Also, invention relates to method of obtaining compound of formula I, pharmaceutical composition based on formula I compound, as well as preventive and therapeutic anti-Helicobacter pylori medicine based on formula I compound.

EFFECT: obtained is novel pyridine derivative, which has anti-Helicobacter pylori activity.

24 cl, 4 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: in claimed invention described is method of obtaining compounds of formula (I) by interaction of compound with base and following interaction of formed compound with compound , where R, R1, R2, R3, R5, T and X have values, given in invention formula.

EFFECT: compounds of formula I are suitable for treatment of a number of conditions, related with substance P and neurokinin.

5 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: in claimed invention described is method of obtaining compounds of formula (I) by interaction of compound with base and following interaction of formed compound with compound , where R, R1, R2, R3, R5, T and X have values, given in invention formula.

EFFECT: compounds of formula I are suitable for treatment of a number of conditions, related with substance P and neurokinin.

5 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to compounds of formula (IC-2), to their pharmaceutically acceptable salts, N- oxides or solvates. In formula (IC-2) Z represents carbomoyl group, which can be replaced with C1-4 alkyl or hydroxy; R1 represents C1-8 alkyl or C1-8 alkoxy; R4 and R4-1 each independently represent hydrogen atom or C1-8 alkyl; m represents integer number from 1 to 5, when m equals 2 or larger number, all R1 can have same or different values. Invention also relates to compounds, representing 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydro-2-napthlenyl}methyl)-3-azetidinecarbonic acid, 1-({6-[(4-isobutyl-2-methoxybenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalinyl}methyl)-3- azetidinecarbonic acid and other, given in formula of claimed invention.

EFFECT: obtaining pharmaceutical composition, which has agonistic activity with respect to EDG-1, EDG-6 and/or EDG-8, containing as active component invention compound, to method of prevention and/or treatment of disease, conditioned by EDG-1, EDG-6 and/or EDG-8 invention compounds, to method of prevention and/or treatment of disseminated sclerosis and method of immune reaction suppression and/or induction of lymphopenia, to application of invention compounds for obtaining medication for prevention and/or treatment of disease, conditioned by EDG-1, EDG-6 and/or EDG-8, to application of compounds for obtaining medication for prevention and/or treatment of disseminated sclerosis, to application of compounds for obtaining immunodepresant and/or medication inducing lymphopenia and to crystal forms of some individual compounds.

17 cl, 10 dwg, 5 tbl, 251 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to compounds of formula (IC-2), to their pharmaceutically acceptable salts, N- oxides or solvates. In formula (IC-2) Z represents carbomoyl group, which can be replaced with C1-4 alkyl or hydroxy; R1 represents C1-8 alkyl or C1-8 alkoxy; R4 and R4-1 each independently represent hydrogen atom or C1-8 alkyl; m represents integer number from 1 to 5, when m equals 2 or larger number, all R1 can have same or different values. Invention also relates to compounds, representing 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydro-2-napthlenyl}methyl)-3-azetidinecarbonic acid, 1-({6-[(4-isobutyl-2-methoxybenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalinyl}methyl)-3- azetidinecarbonic acid and other, given in formula of claimed invention.

EFFECT: obtaining pharmaceutical composition, which has agonistic activity with respect to EDG-1, EDG-6 and/or EDG-8, containing as active component invention compound, to method of prevention and/or treatment of disease, conditioned by EDG-1, EDG-6 and/or EDG-8 invention compounds, to method of prevention and/or treatment of disseminated sclerosis and method of immune reaction suppression and/or induction of lymphopenia, to application of invention compounds for obtaining medication for prevention and/or treatment of disease, conditioned by EDG-1, EDG-6 and/or EDG-8, to application of compounds for obtaining medication for prevention and/or treatment of disseminated sclerosis, to application of compounds for obtaining immunodepresant and/or medication inducing lymphopenia and to crystal forms of some individual compounds.

17 cl, 10 dwg, 5 tbl, 251 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to urology, and can be used in treatment of urolythiasis. For this purpose irrigation of kidney cavity with lytholytic solution is performed. Lytholytic solution includes at least one complexon and ampicillin in amount 0.2-0.3 wt %. As complexon used is mixture in amount 3.4-3.9 wt %. Mixture contains disodium salt of ethylenediamintetraacetic acid 0.9-1.1 wt % and potassium citrate 2.5-2.8 wt %. Irrigation is performed at temperature 36.8-37.2°C, with constant rate of lytholytic solution supply, selected within 1-5 ml/min.

EFFECT: method ensures efficient lytholysis of oxalate calculi with simultaneous dissolution of urate and phosphate inclusions at lower concentrations of lytholytic solutions, which reduces kidney trauma and ensures prevention of complications associated with bacterial infection.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and relates in particular to medication for women, which has contraceptive and protective action against inflectional diseases: herpes, HIV infections, viral disease. Medication for vaginal application, possessing contraceptive and protective against inflectional diseases action contains actively-acting components and target base. As actively-acting components medication contains contraceptive, bactericidal, anti-inflammatory preparations, and as target base it contains gel-forming biocompatible polymers and L-lysin hydrochloride with specified component ratio per 1 g. Medication presents gel, ointment, cream, liniment.

EFFECT: medication not only has contraceptive action, but also makes it possible to simultaneously prevent sexually transmitted infection diseases.

3 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method of obtaining preparations, labelled with rhenium-188 radionuclide, and can be used for obtaining radiopharmaceuticals, used in radionuclide therapy. Method lies in obtaining sterile solution, which consists of ligand, reducer and antioxidant, into which later non-radioactive rhenium in form of sodium perenate (NaReO4) is introduced. Obtained solution is neutralized, filtered, frozen and liophilically dried with further introduction of radioactive rhenium-188 (Na188ReO4) with reaction of complex-formation of 188Re with ligand.

EFFECT: invention makes it possible to obtain sterile radiopharmaceutical, time of preparation of which is reduced to 30-60 minutes due to simplification of technological cycle to one stage.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and relates in particular to medication for women, which has contraceptive and protective action against inflectional diseases: herpes, HIV infections, viral disease. Medication for vaginal application, possessing contraceptive and protective against inflectional diseases action contains actively-acting components and target base. As actively-acting components medication contains contraceptive, bactericidal, anti-inflammatory preparations, and as target base it contains gel-forming biocompatible polymers and L-lysin hydrochloride with specified component ratio per 1 g. Medication presents gel, ointment, cream, liniment.

EFFECT: medication not only has contraceptive action, but also makes it possible to simultaneously prevent sexually transmitted infection diseases.

3 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to obtaining luteolin 7,3'-disulphate. Method of obtaining luteolin 7,3'-disulphate, by extraction of sea grass of family Zosteraceae by ethylene at defined conditions, extract is evaporated, obtained concentrate is solved in distillated water, filtered or centrifuged, filtrate is acidified by hydrochloric acid, stood for a day, sediment is removed, then solution is applied on column with polychrome-1, sorbent is washed with distillated water, and target product is eluted with water solution of ethylene, then alcohol is removed from eluate, target product is dried on spray-type or lyophilic dryer.

EFFECT: method makes it possible to extend spectrum of biologically active substances from available, common sea raw material.

1 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to medication, possessing antioxidant, cardioprotective, antidiabetic, anti-inflammatory, hepatoprotective, antitumoral and antiviral action. Medication, which has antioxidant, cardioprotective, antidiabetic, anti-inflammatory, hepatoprotective, antitumoral and antiviral action, representing luteolin 7,3'-disulphate, is obtained from water-ethanol extract of sea grass of family Zosteraceae.

EFFECT: medication has efficient antioxidant, cardioprotective, antidiabetic, anti-inflammatory, hepatoprotective, antitumoral and antiviral action.

4 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to method of obtaining medication, which has diuretic, antimicrobial and antioxidant action from vegetable raw material. Method of obtaining medication, possessing diuretic, antibacterial and antioxidant action, in which milled grass of agrimonia eupator, collected in flowering phase, is poured with water, drawn on boiling water bath at defined conditions, kept, filtered, brought with water to initial volume and secondary drawn on boiling water bath, cooled, brought to initial volume, evaporated until dry residue is obtained.

EFFECT: medication, obtained by claimed method, has increased activity.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to method of obtaining medication, which possesses gastroprotective action (versions). Method of obtaining medication, possessing gastroprotective action, according to which in milk after autoclaving and cooling added are 2% of activated liquid culture of Bifidobacterium longum D 379 M, dry water-soluble extract of liquorice Glycyrrhiza Glabra L. root and natural zeolite - clinoptilolite, mixture is carefully mixed and thermostated until clot formation with specified acidity. Method of obtaining medication, possessing gastroprotective action, according to which in milk after autoclaving and cooling added are 2% of activated liquid culture of Bifidobacterium longum D 379 M, dry water-soluble extract of liquorice Glycyrrhiza Glabra L. root and natural zeolite - clinoptilolite, mixture is carefully mixed and thermostated until formation of clot with specified acidity.

EFFECT: medication, obtained by upper claimed method (versions) positively influences functional condition of gastrointestinal tract, effectively influences various links of pathological process, normalises malfunctions of microbiogenesis of intestine.

2 cl, 4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary. Preparation for controlling bird ectoparasites contains active substances, as such used is neonol and soya phosphatides with the following component ratio, wt %: neonol - 0.1-0.5; soya phosphatides - 0.1-0.5; water - the remaining part.

EFFECT: preparation makes it possible to eliminate parasites completely by one processing, is not toxic, does not irritate animal's skin, is harmless for animals and environment, its application does not have limitations for lactating animals, young animals and for application of milk and meat, obtained after preparation application.

FIELD: medicine.

SUBSTANCE: invention relates to dentistry, namely to means for teeth care, oral cavity care and prevention of dental diseases. Edible chewing gum with wound-healing effect contains agar, sweetener, extracts of medicinal plants, hydrophilic sorbent, emulsifier, food colouring and water, as extracts of medicinal plants it contains extract from leaves of nettle, yarrow, coltsfoot, as hydrophilic sorbent - apple pectin, as emulsifier - glycerylmonostearate, additionally it contains essential oil of mint, extract of karotenoids from fresh tomato raw material with specified component ratio.

EFFECT: invention provides edible chewing gum, possessing expressed wound-healing, antimicrobial and deodorating activity, as well as non-suppressing saprophyte flora of oral cavity.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to dentistry, namely to means for teeth care, oral cavity care and prevention of dental diseases. Edible chewing gum with wound-healing effect contains agar, sweetener, extracts of medicinal plants, hydrophilic sorbent, emulsifier, food colouring and water, as extracts of medicinal plants it contains extract from leaves of nettle, yarrow, coltsfoot, as hydrophilic sorbent - apple pectin, as emulsifier - glycerylmonostearate, additionally it contains essential oil of mint, extract of karotenoids from fresh tomato raw material with specified component ratio.

EFFECT: invention provides edible chewing gum, possessing expressed wound-healing, antimicrobial and deodorating activity, as well as non-suppressing saprophyte flora of oral cavity.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to dentistry, namely to means for teeth care, oral cavity care and prevention of dental diseases. Edible chewing gum with wound-healing effect contains agar, sweetener, extracts of medicinal plants, hydrophilic sorbent, emulsifier, food colouring and water, as extracts of medicinal plants it contains extract from leaves of nettle, yarrow, coltsfoot, as hydrophilic sorbent - apple pectin, as emulsifier - glycerylmonostearate, additionally it contains essential oil of mint, extract of karotenoids from fresh tomato raw material with specified component ratio.

EFFECT: invention provides edible chewing gum, possessing expressed wound-healing, antimicrobial and deodorating activity, as well as non-suppressing saprophyte flora of oral cavity.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to food and chemical-pharmaceutical industry, namely to creation of a concentrated oil/water emulsion of replacement fat of zero caloric content intended for both appetite control and management, and weight regulation. A composition for appetite control and management, and weight regulation, represents the concentrated emulsion containing replacement fat with zero caloric content selected from a group of saccharose polyesters consisting generally of mixed saccharose octa-, hepta- and hexaesters, triglycerides of caprylic/capric fatty acids, edible Vaseline oil, an emulsifying stabiliser selected from the group: gum arabic, saponin, modified starch, a flavour additive, a preservative, vitamin A, beta carotene and water taken in certain proportions.

EFFECT: received composition shows high functional activity of the developed concentrated emulsions in the prescribed sparing mode of therapy "ГЛ".

3 cl, 1 tbl

Up!